[go: up one dir, main page]

WO1996002641A3 - Produits et procedes relatifs au diagnostic et au traitement prophylactique et therapeutique du synoviosarcome - Google Patents

Produits et procedes relatifs au diagnostic et au traitement prophylactique et therapeutique du synoviosarcome Download PDF

Info

Publication number
WO1996002641A3
WO1996002641A3 PCT/GB1995/001704 GB9501704W WO9602641A3 WO 1996002641 A3 WO1996002641 A3 WO 1996002641A3 GB 9501704 W GB9501704 W GB 9501704W WO 9602641 A3 WO9602641 A3 WO 9602641A3
Authority
WO
WIPO (PCT)
Prior art keywords
synovial sarcoma
prophylactic
diagnosis
materials
therapeutic treatment
Prior art date
Application number
PCT/GB1995/001704
Other languages
English (en)
Other versions
WO1996002641A2 (fr
Inventor
Colin Stephen Cooper
Barry Austin Gusterson
Original Assignee
Cancer Res Campaign Tech
Colin Stephen Cooper
Barry Austin Gusterson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cancer Res Campaign Tech, Colin Stephen Cooper, Barry Austin Gusterson filed Critical Cancer Res Campaign Tech
Priority to AU29865/95A priority Critical patent/AU2986595A/en
Priority to EP95925919A priority patent/EP0769053A2/fr
Publication of WO1996002641A2 publication Critical patent/WO1996002641A2/fr
Publication of WO1996002641A3 publication Critical patent/WO1996002641A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention se rapporte à un procédé visant à diagnostiquer la présence ou l'absence de synoviosarcome et consistant à obtenir un échantillon prélevé dans un tissu d'un patient; mettre l'échantillon en contact avec un élément de liaison spécifique (sbm) qui est spécifique d'un partenaire de liaison (bp), ce dernier étant caractéristique du synoviosarcome, de sorte que la présence de bp dans l'échantillon révèle la présence du synoviosarcome, bp étant absent d'un échantillon équivalent prélevé chez un patient ne souffrant pas de synoviosarcome; et détecter toute liaison de sbm avec son bp. Les caractéristiques des partenaires de liaison du synoviosarcome sont les séquences SSX et SYT et les séquences de fusion de celles-ci. L'invention se rapporte également à des séquences, des réactifs et des procédés thérapeutiques ainsi qu'à des produits pharmaceutiques.
PCT/GB1995/001704 1994-07-19 1995-07-19 Produits et procedes relatifs au diagnostic et au traitement prophylactique et therapeutique du synoviosarcome WO1996002641A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU29865/95A AU2986595A (en) 1994-07-19 1995-07-19 Materials and methods relating to the diagnosis and prophylactic and therapeutic treatment of synovial sarcoma
EP95925919A EP0769053A2 (fr) 1994-07-19 1995-07-19 Produits et procedes relatifs au diagnostic et au traitement prophylactique et therapeutique du synoviosarcome

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9414580.2 1994-07-19
GB9414580A GB9414580D0 (en) 1994-07-19 1994-07-19 Materials and methods relating to the diagnosis of synovial sarcomas

Publications (2)

Publication Number Publication Date
WO1996002641A2 WO1996002641A2 (fr) 1996-02-01
WO1996002641A3 true WO1996002641A3 (fr) 1996-03-07

Family

ID=10758576

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1995/001704 WO1996002641A2 (fr) 1994-07-19 1995-07-19 Produits et procedes relatifs au diagnostic et au traitement prophylactique et therapeutique du synoviosarcome

Country Status (5)

Country Link
EP (1) EP0769053A2 (fr)
AU (1) AU2986595A (fr)
CA (1) CA2195531A1 (fr)
GB (1) GB9414580D0 (fr)
WO (1) WO1996002641A2 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6291658B1 (en) 1997-05-05 2001-09-18 Ludwig Institute For Cancer Research Isolated nucleic acid molecules encoding SSX family members and thereof
US6548064B1 (en) * 1997-05-05 2003-04-15 Ludwig Institute For Cancer Research Isolated peptides consisting of amino acid sequences found in SSX or NY-ESO-1 molecules, which bind to HLA molecules
US6287756B1 (en) * 1997-05-05 2001-09-11 Ludwig Institute For Cancer Research Methods for determining presence of cancer in a sample by determining expression of an SSX gene
US6800730B1 (en) * 1998-10-02 2004-10-05 Ludwig Institute For Cancer Research Isolated peptides which bind to MHC class II molecules, and uses thereof
US7803370B2 (en) 2002-08-30 2010-09-28 Oncotherapy Science, Inc. Method for treating synovial sarcoma
WO2004020668A2 (fr) * 2002-08-30 2004-03-11 Oncotherapy Science, Inc. Methode de traitement du synovialome
EP1648506B1 (fr) * 2003-07-11 2012-02-15 Oncotherapy Science, Inc. Methode de traitement du synovialome
US7910696B2 (en) 2003-07-22 2011-03-22 Ludwig Institute For Cancer Research Ltd. Ssx-2 peptides presented by hla class II molecules
BRPI0621800B8 (pt) 2006-06-21 2022-01-04 Oncotherapy Science Inc anticorpos que se ligam à proteína fzd10, clones de hibridoma, composições farmacêuticas, kit compreendendo os referidos anticorpos, e método para diagnose ou prognose de uma doença que é associada a homólogo fzd10 ou de uma predisposição para desenvolver a doença em um indivíduo
WO2009018018A2 (fr) * 2007-07-31 2009-02-05 University Of Utah Research Foundation Modèle animal d'un sarcome synovial
US8975384B2 (en) 2008-01-31 2015-03-10 Osaka University Tag peptide and use thereof
TWI762516B (zh) 2016-10-06 2022-05-01 日商腫瘤療法 科學股份有限公司 針對ｆｚｄ１０之單株抗體及其用途
CN110660451B (zh) * 2018-06-13 2023-04-28 广州华大基因医学检验所有限公司 确定生物样本中是否存在融合基因的方法、设备及应用
WO2024233388A2 (fr) * 2023-05-05 2024-11-14 Memorial Sloan-Kettering Cancer Center Vaccins contre le sarcome et utilisations associées

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5084566A (en) * 1987-05-04 1992-01-28 Michael Litt DNA probe which reveals a hypervariable region on human chromosone 1

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5084566A (en) * 1987-05-04 1992-01-28 Michael Litt DNA probe which reveals a hypervariable region on human chromosone 1

Non-Patent Citations (13)

* Cited by examiner, † Cited by third party
Title
A.J. CREW ET AL.: "Fusion of SYT to two genes, SSX1 and SSX2, encoding proteins with homology to the Kruppel-associated boc in human synovial sarcoma", EMBO J., vol. 14, no. 10, 15 May 1995 (1995-05-15), OXFORD UNIVERSITY PRESS,GB;, pages 2333 - 2340 *
B. DE LEEUW ET AL.: "Identification of a yeast artificial chromosome (YAC) spanning the synovial sarcoma-specific t(X;18)(11.2;q11.2) breakpoint", GENES, CHROMOSOMES & CANCER, vol. 6, no. 3, WILEY-LISS, INC.; NEW YORK, US, pages 182 - 189 *
B. DE LEEUW ET AL.: "Identification of two alternative fusion genes, SYT-SSX1 and SYT-SSX2, in t(X;18)(p11.2;q11.2)-positive synovial sarcomas", HUMAN MOLECULAR GENETICS, vol. 4, no. 6, OXFORD UNIVERSITY PRESS, UK, pages 1097 - 1099 *
B. DE LEEUW ET AL.: "Molecular cloning of the synovial sarcoma-specific translocation (X;18)(p11.2;q11.2) breakpoint", HUMAN MOLECULAR GENETICS, vol. 3, no. 5, OXFORD UNIVERSITY PRESS, UK, pages 745 - 749 *
B. DE LEEUW ET AL.: "Sublocalization of the synovial sarcoma-associated t(X;18) chromosomal breakpoint in Xp11.2 using cosmid cloning and fluorescence in situ hybridization", ONCOGENE, vol. 8, no. 6, MACMILLAN PRESS LTD.,LONDON,UK, pages 1457 - 1463 *
B.R. REEVES ET AL.: "Characterization of the translocation between chromosomes X and 18 in human synovial sarcomas", ONCOGENE, vol. 4, no. 3, MACMILLAN PRESS LTD.,LONDON,UK, pages 373 - 378 *
C. COOPER ET AL.: "Characterization of novel genes SYT and SSX involved in the t(X;18)(p11.2;q11.2) translocation found in human synovial sarcoma", J. CELL. BIOCHEM. SUPPL. 0 (19A),, WILEY LISS, NEW YORK, US, pages 50 *
D. OLDE WEGHUIS ET AL.: "A synovial sarcoma with a complex t(X;18;5;4) and a break in the ornithine aminotransferase (OAT)L1 cluster on Xp11.2", GENES, CHROMOSOMES & CANCER, vol. 9, no. 4, WILEY-LISS, INC.; NEW YORK, US, pages 288 - 291 *
DE LEEUW, B. ET AL: "Distinct Xp11.2 breakpoint regions in synovial sarcoma revealed by metaphase and interphase FISH: relationship to histologic subtypes", CANCER GENET. CYTOGENET. (1994), 73(2), 89-94 CODEN: CGCYDF;ISSN: 0165-4608 *
J. CLARK ET AL.: "Identification of novel genes, SYT and SSX, involved in the (tX;18)(p11.2;q11.2) translocation found in human synovial sarcoma", NATURE GENETICS, vol. 7, no. 4, NATURE PUBLISHING CO., NEW YORK, US, pages 502 - 508 *
J.C. KNIGHT ET AL.: "Localization of the synovial sarcoma t(X;18)(p11.2) breakpoint by flourescence in situ hybridization", HUMAN MOLECULAR GENETICS, vol. 1, no. 8, OXFORD UNIVERSITY PRESS, UK, pages 633 - 637 *
J.M. SHIPLEY ET AL.: "The t(X;18)(p11.2;q11.2) translocation found in human synovial sarcomas involves two distinct loci on the X chromosome", ONCOGENE, vol. 9, no. 5, MACMILLAN PRESS LTD.,LONDON,UK, pages 1447 - 1453 *
M. LITT AND N.E. BUROKER: "DNA probe p1-p79 consensus sequence", EMBL-SEQUENCE DATABASE, 22 May 1992 (1992-05-22), HEIDELBERG, BRD; *

Also Published As

Publication number Publication date
CA2195531A1 (fr) 1996-02-01
EP0769053A2 (fr) 1997-04-23
WO1996002641A2 (fr) 1996-02-01
GB9414580D0 (en) 1994-09-07
AU2986595A (en) 1996-02-16

Similar Documents

Publication Publication Date Title
WO1996002641A3 (fr) Produits et procedes relatifs au diagnostic et au traitement prophylactique et therapeutique du synoviosarcome
WO1998053076A3 (fr) Composes permettant de diagnostiquer la tuberculose et leurs procedes d'utilisation
WO1998016645A3 (fr) Composes et procedes pour diagnostiquer la tuberculose
MX9801687A (es) Compuestos y metodos para el diagnostico de tuberculosis.
AU4756896A (en) Test apparatus, system and method for the detection of test samples
EP1318399A3 (fr) Détection passive d'un échantillon pour commencer une analyse
DE59708311D1 (de) Volumenunabhängiger diagnostischer Testträger und Verfahren zur Bestimmung von Analyten mit dessen Hilfe
EP0791176A4 (fr) Dispositif et procede de detection
EP0987550A3 (fr) Dispositif analytique et méthode d'utilisation
EP0890840A3 (fr) Essai pour la dégradation de collagène in-vivo
HRP970401A2 (en) Diagnostic test element with multilayered test field and method to assay analytes using it
AU4303196A (en) Test set for analysis of body fluids, process for producing it and analytical procedure
AU7260496A (en) A method and diagnostic test kit for use in aiding the diagnosis of fibromyyalgia and chronic fatigue syndrome (CFS)
WO2001057537A3 (fr) Procedes servant a diagnostiquer la maladie d'alzheimer
AU2514195A (en) Method of rapid analyte detection
EP0882985A3 (fr) Détermination immunochimiques des analytes multivalents
WO1999024611A3 (fr) Detection d'analyte par utilisation de sondes a double marquage
AU5144696A (en) Method of examining household dust
EP1652918A3 (fr) Methodes de detection d'interactions entre proteines utilisant des peptides a conformation contrainte
EP0386166A4 (en) Protamine-reactive igm antibodies
AU3140497A (en) Methods and kits for the detection of endotoxin
CA2172243A1 (fr) Methode pour l'analyse quantitative des liquides organiques
WO2000028045A3 (fr) Hydrolases humaines
AU4018397A (en) (m. tuberculosis) complex members mycobacteria specific nucleic acid fragments and their applications for the detection and differential diagnosis of (m. tuberculosis) complex members
AU3239895A (en) Method of using hyaluronic acid for the detection, location and diagnosis of tumors

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LT LU LV MD MG MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TT UA UG US UZ VN

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): KE MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2195531

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1995925919

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 289893

Country of ref document: NZ

WWP Wipo information: published in national office

Ref document number: 1995925919

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 1995925919

Country of ref document: EP